Institut de Recherches Cliniques de Montréal (IRCM) and Département de Microbiologie et Immunologie, Université de Montréal, Montréal, QC H2W 1R7, Canada.
Blood. 2010 Mar 25;115(12):2462-72. doi: 10.1182/blood-2009-08-239822. Epub 2010 Jan 14.
The GFI1 gene encodes a transcriptional repressor, which regulates myeloid differentiation. In the mouse, Gfi1 deficiency causes neutropenia and an accumulation of granulomonocytic precursor cells that is reminiscent of a myelodysplastic syndrome. We report here that a variant allele of GFI1 (GFI1(36N)) is associated with acute myeloid leukemia (AML) in white subjects with an odds ratio of 1.6 (P < 8 x 10(-5)). The GFI1(36N) variant occurred in 1806 AML patients with an allele frequency of 0.055 compared with 0.035 in 1691 healthy control patients in 2 independent cohorts. We observed that both GFI1 variants maintain the same activity as transcriptional repressors but differ in their regulation by the AML1/ETO (RUNX1/RUNX1T1) fusion protein produced in AML patients with a t(8;21) translocation. AML1/ETO interacts and colocalizes with the more common GFI1(36S) form in the nucleus and inhibits its repressor activity. However, the variant GFI1(36N) protein has a different subnuclear localization than GFI1(36S). As a consequence, AML1/ETO does not colocalize with GFI1(36N) and is unable to inhibit its repressor activity. We conclude that both variants of GFI1 differ in their ability to be regulated by interacting proteins and that the GFI1(36N) variant form exhibits distinct biochemical features that may confer a predisposition to AML.
GFI1 基因编码一种转录抑制因子,调节髓系分化。在小鼠中,GFI1 缺失导致中性粒细胞减少和粒细胞单核细胞前体细胞的积累,这类似于骨髓增生异常综合征。我们在这里报告,GFI1 的一种变异等位基因(GFI1(36N))与白人急性髓系白血病(AML)相关,优势比为 1.6(P<8x10(-5))。与 1691 名健康对照患者中的 0.035 相比,两个独立队列中的 1806 名 AML 患者中的 GFI1(36N) 变异等位基因的等位基因频率为 0.055。我们观察到两种 GFI1 变异体都保持相同的转录抑制活性,但在 AML 患者中由 AML1/ETO(RUNX1/RUNX1T1)融合蛋白调节时存在差异,AML1/ETO 易位产生。AML1/ETO 在核内与更常见的 GFI1(36S) 形式相互作用并共定位,并抑制其抑制活性。然而,变异体 GFI1(36N) 蛋白的亚核定位与 GFI1(36S) 不同。因此,AML1/ETO 不会与 GFI1(36N) 共定位,并且无法抑制其抑制活性。我们得出结论,两种 GFI1 变异体在与相互作用蛋白的调节能力上存在差异,并且 GFI1(36N) 变异体形式表现出不同的生化特征,这可能导致 AML 的易感性。